At a Glance
ERIS Lifesciences, the youngest brat among India’s top 20 pharma companies, posted Q1 FY26 revenue of ₹773 Cr (↑7% YoY) and PAT ₹125 Cr (↑42% YoY). Margins stayed rock-solid at 36%, but investors are choking on the P/E of 64. The stock’s trading at 8.6× book value, making it more expensive than a branded multivitamin.
Introduction
ERIS is not about mass generics; it’s all about branded formulations in chronic segments like diabetes, cardiology, and neurology. They’re the cool kid selling premium drugs at premium margins. But pharma is a tough game – with acquisitions, regulations, and R&D burn always lurking. The latest results? Strong, but the valuation? Stronger than their Vitamin D3 dosage.
Business Model (WTF Do They Even Do?)
- Core Biz: Branded prescription drugs in India.
- Therapeutic Areas: Diabetes, cardiology, metabolic disorders, dermatology.
- Strategy: Aggressive acquisitions (Biocon’s branded formulations, Swiss Parenterals stake).
- Roast: They buy growth like influencers buy followers – expensive but effective.
Financials Overview
Q1 FY26 Highlights
- Revenue: ₹773 Cr (↑7% YoY)
- Operating Profit: ₹277 Cr (OPM 36%)
- PAT: ₹125 Cr (↑42% YoY)
- EPS: ₹8.66
TTM
- Revenue: ₹2,947 Cr
- PAT: ₹411 Cr
- Book Value: ₹210
- P/E: 63.8
Commentary: Pharma margins are juicy, profits improving, but debt from acquisitions is heavy.
Valuation
1. P/E Method
- EPS ₹28.4 × Fair P/E (30) → ₹850.
2. EV/EBITDA
- EBITDA FY25 ₹1,018 Cr × 12 → EV ₹12,216 Cr.
- Current EV ~₹24,700 Cr → 2× Overvalued.
3.
